> Details

Beres, Bence; Yusenko, Maria; Peterfi, Lehel; Kovacs, Gyula; Banyai, Daniel

Matrix metalloproteinase 12 is an independent prognostic factor predicting postoperative relapse of conventional renal cell carcinoma - a short report

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Matrix metalloproteinase 12 is an independent prognostic factor predicting postoperative relapse of conventional renal cell carcinoma - a short report
  • Contributor: Beres, Bence; Yusenko, Maria; Peterfi, Lehel; Kovacs, Gyula; Banyai, Daniel
  • Published: Springer Science and Business Media LLC, 2022
  • Published in: Cellular Oncology, 45 (2022) 1, Seite 193-198
  • Language: English
  • DOI: 10.1007/s13402-021-00650-9
  • ISSN: 2211-3428; 2211-3436
  • Keywords: Cancer Research ; Oncology ; Molecular Medicine ; General Medicine
  • Origination:
  • Footnote:
  • Description: AbstractPurposeApproximately 15% of clinically localised conventional renal cell carcinomas (cRCC) develop metastases within 5 years of follow-up. Sarcomatous cRCC is a highly malignant cancer of the kidney. The aim of our study was to identify biomarkers for estimating the postoperative progression of cRCCs.MethodsGlobal microarray-based gene expression analysis of RCCs with and without sarcomatous changes revealed that a high MMP12 expression was associated with a sarcomatous histology. Additionally, we analysed MMP12 expression using a multi-tissue array comprising 736 cRCC patients without metastasis at the time of surgery. The median follow-up time was 66 ± 29 months.ResultsImmunohistochemistry revealed MMP12 expression in 187 of 736 cRCCs with good follow-up data. Subsequent Kaplan–Meier analysis revealed that patients with MMP12 positive tumours exhibited a significantly shorter tumour-free survival (p < 0.001). In multivariate Cox regression analysis a weak to strong MMP12 expression indicated a 2.4–2.8 times higher risk of postoperative tumour relapse (p < 0.001;p < 0.003, respectively).ConclusionsMMP12 may serve as a biomarker to estimate postoperative cRCC relapse and as a possible target for penfluridol therapy.